Search

Your search keyword '"Ricci Maccarini L"' showing total 11 results
Start Over Author "Ricci Maccarini L"
11 results on '"Ricci Maccarini L"'

8. Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms

Author

P, De Iaco, I, Strada, L, Ricci Maccarini, L, Orazi, B, Di Marcoberardino, F, Pozzati, M, Rossi, M, Tsivian, S, Venturoli, De Iaco P., Strada I., Ricci Maccarini L., Orazi L., Di Marcoberardino B., Pozzati F., Rossi M., Tsivian M., and Venturoli S.

Subjects
Adult, Ovarian Neoplasms, Surgical Sponges, Time Factors, Genital Neoplasms, Female, thrombin coated patch, Lymphocele, Fibrinogen coated patch, Carcinoma, Lumbosacral Region, Thrombin, Fibrinogen, Middle Aged, Hemostatics, Endometrial Neoplasms, Pelvis, Drug Combinations, Treatment Outcome, lumbar-aortic lymphadenectomy, Hysterectomy, Vaginal, Humans, Lymph Node Excision, Female, Collagen, Neoplasm Staging
Published
2011

9. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy

Author

MARTONI, ANDREA, FANTI, STEFANO, ZAMAGNI, CLAUDIO, DE IACO, PIERANDREA, D'ERRICO, ANTONIETTA, CASTELLUCCI, PAOLO, QUERCIA, SARA, RICCI MACCARINI, LUCIA, LOPCI, EGESTA, Rosati M, Musto A, Bernardi A., Martoni AA, Fanti S, Zamagni C, Rosati M, De Iaco P, D'Errico Grigioni A, Castellucci P, Quercia S, Musto A, Ricci Maccarini L, Lopci E, and Bernardi A.

Subjects
Adult, Ovarian Neoplasms, Fluorine Radioisotopes, Paclitaxel, Middle Aged, OVARIAN CANCER, Neoadjuvant Therapy, Carboplatin, PET, Chemotherapy, Adjuvant, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron-Emission Tomography, Humans, Female, Radiopharmaceuticals, Tomography, X-Ray Computed, Aged, Neoplasm Staging
Abstract

AIM: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses. [(18)F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration. METHODS: Consecutive patients with AOC unsuitable for optimal up front surgery and fit for na-CHT were monitored by FDG-PET/CT at baseline and after 3 and 6 courses of carboplatin-paclitaxel CHT. At the end of na-CHT patients were re-evaluated to undergo definitive optimal surgery (i.e. without post-surgical residual disease). Percentage changes in maximal standardized uptake value (∆-SUVmax) were compared with the pathological response. Only patients with pathological complete response (pCR) or minimal residual disease (pMRD) were considered as pathological responders (pR), while all the other cases were considered non-responders (NR). RESULTS: Baseline FDG-PET/CT was abnormal in all 42 enrolled patients (median SUVmax 11, range 3-20). After 3 and 6 courses median SUVmax decreased to 3 (

Published
2010

10. [Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms].

Author

De Iaco P, Strada I, Ricci Maccarini L, Orazi L, Di Marcoberardino B, Pozzati F, Rossi M, Tsivian M, and Venturoli S

Subjects
Adult, Carcinoma surgery, Drug Combinations, Endometrial Neoplasms surgery, Female, Humans, Hysterectomy, Vaginal, Lumbosacral Region, Lymph Node Excision methods, Middle Aged, Neoplasm Staging, Ovarian Neoplasms secondary, Ovarian Neoplasms surgery, Pelvis, Surgical Sponges, Time Factors, Treatment Outcome, Collagen therapeutic use, Fibrinogen therapeutic use, Genital Neoplasms, Female surgery, Hemostatics therapeutic use, Lymph Node Excision adverse effects, Lymphocele prevention & control, Thrombin therapeutic use
Published
2011

11. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.

Author

Martoni AA, Fanti S, Zamagni C, Rosati M, De Iaco P, D'Errico Grigioni A, Castellucci P, Quercia S, Musto A, Ricci Maccarini L, Lopci E, and Bernardi A

Subjects
Adult, Aged, Carboplatin administration & dosage, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Paclitaxel administration & dosage, Positron-Emission Tomography, Predictive Value of Tests, Radiopharmaceuticals, Tomography, X-Ray Computed, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms drug therapy
Abstract

Aim: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses. [(18)F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration., Methods: Consecutive patients with AOC unsuitable for optimal up front surgery and fit for na-CHT were monitored by FDG-PET/CT at baseline and after 3 and 6 courses of carboplatin-paclitaxel CHT. At the end of na-CHT patients were re-evaluated to undergo definitive optimal surgery (i.e. without post-surgical residual disease). Percentage changes in maximal standardized uptake value (∆-SUVmax) were compared with the pathological response. Only patients with pathological complete response (pCR) or minimal residual disease (pMRD) were considered as pathological responders (pR), while all the other cases were considered non-responders (NR)., Results: Baseline FDG-PET/CT was abnormal in all 42 enrolled patients (median SUVmax 11, range 3-20). After 3 and 6 courses median SUVmax decreased to 3 (<2-21) and <2, i.e. value equal to normal surrounding tissues uptake (<2-17), respectively. After 3 courses, 17 (40%) patients presented ∆-SUVmax=100%, (i.e. SUVmax <2): 15 of them (88%) subsequently resulted pR and achieved no postsurgical residual disease at the end of na-CHT, while 2 (12%) were NR with postsurgical residual tumor ≤ 1cm. Out of 25 patients with ∆-SUVmax <100% after 3 courses, 6 (24%) were pR and 19 (76%) NR at the end of na-CHT., Conclusion: Patients with AOC who present normalization of SUVmax after 3 courses of na-CT have a high likelihood of benefiting from 3 additional courses in order to obtain pCR or pMDR and receiving optimal surgery.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results